Our United Kingdom distributor, Vertec, will be attending this year's MPEC (Medical Physics and Engineering Conference). It will be held in Glasgow, Scotland, from August 31st - September 2nd. More information about the conference can be found by clicking here. To visit Vertec's website, please click here.

Our Australian distributor, NL-Tec, will be at the 2014 Combined Scientific Meeting, held in Melbourne, Australia. This conference runs from September 4 - 7. To learn more about the conference, please click here. To visit NL-Tec's website, please click here.

For more information about our distributors such as contact information, you may visit the distributor section of our website.

We appreciate our distributors, and look forward to the upcoming conferences.

Two of Diacor's distributors, Scanflex, who serves Denmark, Finland, Norway, and Sweden, and Horber Lauro, who serves Colombia, have made significant updates to their websites. They are now able to highlight Diacor's products even better! We are all excited for the updates and encourage everyone to go to their websites and check them out! To visit Scanflex's website, please visit http://www.scanflex.se/Patientfoerflyttning-2.htm. To view Horber Lauro's site, please visit http://horber-lauro.com/productos/radioterapia/

Diacor is pleased to announce that we will be attending this year's ABS Meeting and ESTRO Forum. This year's ABS Meeting will be held in New Orleans, Louisiana, April 18th-20th, with the ESTRO Forum held during the same time from April 19th-23rd in Geneva, Switzerland. Diacor will be at both events to talk about their products. Diacor will be at ABS with product information on the Zephyr hdr, and will have both the Zephyr hdr and Zephyr xl at Geneva. Please stop by our booths and check us out! We'd love to see you.

New figures released by Cancer Research UK show that by 2027 50 out of 100 men will develop some form of cancer at some point during their lives, in the United Kingdom. This is compared to 44 out of 100 in 2010. Women also saw an increase from 40 to 44 out of 100 in the same time period. One of the causes for this could be that people will live longer over the next 15 years, meaning that they would have an increased risk of developing cancer. The cancers that are set to increase the most in the next 15 years are prostate, bowel, and melanoma cancer. While the risk of developing cancer is increasing, the rate at which people are surviving cancer is as well. With new techniques to detect the disease and new treatments, survival has doubled in the last 40 years. For more information, please visit Cancer Research UK's website by clicking here.

Researchers from the University of Lund (Sweden), have reported in the official journal of the American Dairy Science Association, Journal of Dairy Science, that drinking milk can protect from colon cancer progression. Milk had been previously known to reduce the risk of diabetes and metabolic syndrome, and even positively impact your brain and mental performance. The researchers found that Lactoferricin4-14, a protein found in milk, considerably reduced the growth rate of colon cancer cells over the long term. To read the abstract and to purchase the full article, please click here.

The largest study ever on whether cell phones cause tumors to the central nervous system has found that cell phones do not cause tumors. The Danish study involved an 18 year period involving 358,403 people, self reportedly the largest study on the topic. The researchers determined that within a 10 year period of cell phone use, that cell phones do not cause brain tumors; however, longer periods than 10 years still need to be examined. To see the abstract and full article, please click here.

In a new report released by MacMillan, a United Kingdom cancer charity, exercise can greatly benefit cancer survivors. Breast cancer patients' risk of recurrence and dying from the disease can be reduced by 40%, bowel cancer patients' by up to 50%, and prostate cancer patients' by up to 30%. Despite the findings however, most health professionals are not aware of this and are not talking to their patients about it. To view the report on MacMillan's website, please click here.